An immunogenic cell death-related signature predicts prognosis and immunotherapy response in stomach adenocarcinoma.
Immunogenic cell death
Immunotherapy
Prognosis
Stomach adenocarcinoma
Tumor microenvironment
Journal
Apoptosis : an international journal on programmed cell death
ISSN: 1573-675X
Titre abrégé: Apoptosis
Pays: Netherlands
ID NLM: 9712129
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
accepted:
28
07
2023
medline:
1
11
2023
pubmed:
15
8
2023
entrez:
14
8
2023
Statut:
ppublish
Résumé
The immunogenic cell death (ICD) is a specific type of regulatory cell death (RCD), which induces adaptive immunity against antigens of dead cells. ICDs have received increasing attention for their potential role in tumor microenvironment reprogramming and immunotherapy. However, the relationship between ICD-related features and stomach adenocarcinoma (STAD) prognosis, immune cell infiltration and immunotherapy remains unclear. Patients were divided into different ICD-related subtypes by consensus clustering. The differences in prognosis, Tumor microenvironment (TME), and immune checkpoint expression between different ICD-related subtypes were systematically assessed. Additionally, we constructed an ICD-related gene risk score (ICDRS). We systematically analyzed the correlation between ICDRS and prognosis, TME, immunotherapy response and drug sensitivity of gastric cancer. In addition, we explored the role of TGM2 in promoting gastric cancer progression through in vitro experiments. We identified three ICD-associated subtypes by consensus clustering. The ICD gene was highly expressed in Cluster B. Compared with the other two subtypes, Cluster B had better prognosis, higher immune response signaling activity, massive immune cell infiltration and lower tumor purity. Immune checkpoint (ICP) and human leukocyte antigen (HLA) related genes were also highly expressed in Cluster B. In addition, we found that ICDRS is an effective indicator for predicting the prognosis and immune efficacy of STAD. The low ICDRS group has the characteristics of good prognosis, high tumor mutation burden (TMB), high microsatellite instability (MSI), and sensitivity to immunotherapy, while the high ICDRS group is prone to immune escape and immunotherapy resistance. In addition, we found that down-regulating TGM2 gene can inhibit the proliferation and migration of gastric cancer cells through in vitro experiments. Our study found that the model based on ICD features is helpful to clarify the TME characteristics of STAD, and has important clinical significance for evaluating the prognosis and immunotherapy response of STAD patients. TGM2 plays an important role in the progression of STAD, suggesting that TGM2 can be used as a new target for the treatment of STAD.
Identifiants
pubmed: 37580435
doi: 10.1007/s10495-023-01879-5
pii: 10.1007/s10495-023-01879-5
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1564-1583Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
pubmed: 30207593
doi: 10.3322/caac.21492
Gambardella V, Castillo J, Tarazona N, Gimeno-Valiente F, Martínez-Ciarpaglini C, Cabeza-Segura M et al (2020) The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev 86:102015
pubmed: 32248000
doi: 10.1016/j.ctrv.2020.102015
Russo AE, Strong VE (2019) Gastric cancer etiology and management in Asia and the West. Annu Rev Med 70:353–367
pubmed: 30355265
doi: 10.1146/annurev-med-081117-043436
Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K et al (2020) Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 26(4):566–576
pubmed: 32251400
doi: 10.1038/s41591-020-0805-8
Sheih A, Voillet V, Hanafi LA, DeBerg HA, Yajima M, Hawkins R et al (2020) Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. Nat Commun 11(1):219
pubmed: 31924795
pmcid: 6954177
doi: 10.1038/s41467-019-13880-1
Riley RS, June CH, Langer R, Mitchell MJ (2019) Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov 18(3):175–196
pubmed: 30622344
pmcid: 6410566
doi: 10.1038/s41573-018-0006-z
Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807–821
pubmed: 32612154
pmcid: 7395159
doi: 10.1038/s41423-020-0488-6
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science (New York, NY) 359(6382):1350–1355
doi: 10.1126/science.aar4060
Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4):707–723
pubmed: 28187290
pmcid: 5391692
doi: 10.1016/j.cell.2017.01.017
Nagarsheth N, Wicha MS, Zou W (2017) Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 17(9):559–572
pubmed: 28555670
pmcid: 5731833
doi: 10.1038/nri.2017.49
Shi Y, Lammers T (2019) Combining Nanomedicine and Immunotherapy. Acc Chem Res 52(6):1543–1554
pubmed: 31120725
pmcid: 7115879
doi: 10.1021/acs.accounts.9b00148
Smyth MJ, Ngiow SF, Ribas A, Teng MW (2016) Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol 13(3):143–158
pubmed: 26598942
doi: 10.1038/nrclinonc.2015.209
Jin MZ, Jin WL (2020) The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther 5(1):166
pubmed: 32843638
pmcid: 7447642
doi: 10.1038/s41392-020-00280-x
Li Z, Lai X, Fu S, Ren L, Cai H, Zhang H et al (2022) Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency. Adv Sci 9(22):e2201734
doi: 10.1002/advs.202201734
Fucikova J, Kepp O, Kasikova L, Petroni G, Yamazaki T, Liu P et al (2020) Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death Dis 11(11):1013
pubmed: 33243969
pmcid: 7691519
doi: 10.1038/s41419-020-03221-2
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB et al (2020) Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 8(1):e000337
pubmed: 32209603
pmcid: 7064135
doi: 10.1136/jitc-2019-000337
Jin MZ, Wang XP (2021) Immunogenic cell death-based cancer vaccines. Front Immunol 12:697964
pubmed: 34135914
pmcid: 8200667
doi: 10.3389/fimmu.2021.697964
Alzeibak R, Mishchenko TA, Shilyagina NY, Balalaeva IV, Vedunova MV, Krysko DV (2021) Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. J Immunother Cancer 9(1):e001926
pubmed: 33431631
pmcid: 7802670
doi: 10.1136/jitc-2020-001926
Lau TS, Chan LKY, Man GCW, Wong CH, Lee JHS, Yim SF et al (2020) Paclitaxel induces immunogenic cell death in ovarian cancer via TLR4/IKK2/SNARE-dependent exocytosis. Cancer Immunol Res 8(8):1099–1111
pubmed: 32354736
doi: 10.1158/2326-6066.CIR-19-0616
Wang X, Wu S, Liu F, Ke D, Wang X, Pan D et al (2021) An Immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma. Front Immunol 12:781466
pubmed: 34868055
pmcid: 8640500
doi: 10.3389/fimmu.2021.781466
Clifton GT, Rothenberg M, Ascierto PA, Begley G, Cecchini M, Eder JP et al (2023) Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop. J Immunother Cancer 11(6):e006773
pubmed: 37290925
pmcid: 10254706
doi: 10.1136/jitc-2023-006773
Liu YT, Sun ZJ (2021) Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics 11(11):5365–5386
pubmed: 33859752
pmcid: 8039952
doi: 10.7150/thno.58390
Turley SJ, Cremasco V, Astarita JL (2015) Immunological hallmarks of stromal cells in the tumour microenvironment. Nat Rev Immunol 15(11):669–682
pubmed: 26471778
doi: 10.1038/nri3902
Kroemer G, Galassi C, Zitvogel L, Galluzzi L (2022) Immunogenic cell stress and death. Nat Immunol 23(4):487–500
pubmed: 35145297
doi: 10.1038/s41590-022-01132-2
Ahmed A, Tait SWG (2020) Targeting immunogenic cell death in cancer. Mol Oncol 14(12):2994–3006
pubmed: 33179413
pmcid: 7718954
doi: 10.1002/1878-0261.12851
Kroemer G, Galluzzi L, Kepp O, Zitvogel L (2013) Immunogenic cell death in cancer therapy. Annu Rev Immunol 31:51–72
pubmed: 23157435
doi: 10.1146/annurev-immunol-032712-100008
Li Y, Zhang H, Li Q, Zou P, Huang X, Wu C et al (2020) CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer. Cancer Lett 495:12–21
pubmed: 32941949
doi: 10.1016/j.canlet.2020.09.011
Duan X, Chan C, Lin W (2019) Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed Engl 58(3):670–680
pubmed: 30016571
doi: 10.1002/anie.201804882
Fu L, Zhou X, He C (2021) Polymeric nanosystems for immunogenic cell death-based cancer immunotherapy. Macromol Biosci 21(7):e2100075
pubmed: 33885225
doi: 10.1002/mabi.202100075
Hsieh YF, Liu GY, Lee YJ, Yang JJ, Sándor K, Sarang Z et al (2013) Transglutaminase 2 contributes to apoptosis induction in Jurkat T cells by modulating Ca
pubmed: 24349085
pmcid: 3859493
doi: 10.1371/journal.pone.0081516
Li C, Cai J, Ge F, Wang G (2018) TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma. Int J Mol Med 42(4):1799–1808
pubmed: 30015899
pmcid: 6108886
Fok JY, Ekmekcioglu S, Mehta K (2006) Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 5(6):1493–1503
pubmed: 16818508
doi: 10.1158/1535-7163.MCT-06-0083
Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH et al (2010) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 136(4):493–502
pubmed: 19763620
doi: 10.1007/s00432-009-0681-6
Yang P, Yu D, Zhou J, Zhuang S, Jiang T (2019) TGM2 interference regulates the angiogenesis and apoptosis of colorectal cancer via Wnt/β-catenin pathway. Cell Cycle (Georgetown, Tex) 18(10):1122–1134
pubmed: 31010374
doi: 10.1080/15384101.2019.1609831
Agnihotri N, Kumar S, Mehta K (2013) Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res 15(1):202
pubmed: 23673317
pmcid: 3745644
doi: 10.1186/bcr3371
Naselsky W, Adhikary G, Shrestha S, Chen X, Ezeka G, Xu W et al (2022) Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype. Mol Carcinog 61(6):537–548
pubmed: 35319795
pmcid: 10074999
doi: 10.1002/mc.23399
Zhao Q, Cao L, Guan L, Bie L, Wang S, Xie B et al (2019) Immunotherapy for gastric cancer: dilemmas and prospect. Brief Funct Genom 18(2):107–112
doi: 10.1093/bfgp/ely019
Vrána D, Matzenauer M, Neoral Č, Aujeský R, Vrba R, Melichar B et al (2018) From tumor immunology to immunotherapy in gastric and esophageal cancer. Int J Mol Sci 20(1):13
pubmed: 30577521
pmcid: 6337592
doi: 10.3390/ijms20010013
Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L (2016) Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol 27(8):1482–1492
pubmed: 27069014
doi: 10.1093/annonc/mdw168
Lytle NK, Barber AG, Reya T (2018) Stem cell fate in cancer growth, progression and therapy resistance. Nat Rev Cancer 18(11):669–680
pubmed: 30228301
pmcid: 8388042
doi: 10.1038/s41568-018-0056-x
Bajaj J, Diaz E, Reya T (2020) Stem cells in cancer initiation and progression. J Cell Biol 219(1):e201911053
pubmed: 31874116
doi: 10.1083/jcb.201911053
Ferguson LP, Diaz E, Reya T (2021) The role of the microenvironment and immune system in regulating stem cell fate in cancer. Trends Cancer 7(7):624–634
pubmed: 33509688
pmcid: 8318571
doi: 10.1016/j.trecan.2020.12.014